CA2304312A1 - Acides nucleiques s'hybridant a des cibles multiples, leur preparation, compositions, formulation, trousses et applications - Google Patents

Acides nucleiques s'hybridant a des cibles multiples, leur preparation, compositions, formulation, trousses et applications Download PDF

Info

Publication number
CA2304312A1
CA2304312A1 CA002304312A CA2304312A CA2304312A1 CA 2304312 A1 CA2304312 A1 CA 2304312A1 CA 002304312 A CA002304312 A CA 002304312A CA 2304312 A CA2304312 A CA 2304312A CA 2304312 A1 CA2304312 A1 CA 2304312A1
Authority
CA
Canada
Prior art keywords
seq
frag
ggg
ggc
ctg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304312A
Other languages
English (en)
Inventor
Jonathan W. Nyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/093,972 external-priority patent/US6825174B2/en
Application filed by Individual filed Critical Individual
Publication of CA2304312A1 publication Critical patent/CA2304312A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Oligonucléotides antisens se fixant à deux ou plusieurs cibles d'ARN.
CA002304312A 1997-09-17 1998-09-17 Acides nucleiques s'hybridant a des cibles multiples, leur preparation, compositions, formulation, trousses et applications Abandoned CA2304312A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5916097P 1997-09-17 1997-09-17
US60/059,160 1997-09-17
US09/093,972 1998-06-09
US09/093,972 US6825174B2 (en) 1995-06-07 1998-06-09 Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
PCT/US1998/019419 WO1999013886A1 (fr) 1997-09-17 1998-09-17 Acides nucleiques s'hybridant a des cibles multiples, leur preparation, compositions, formulation, trousses et applications

Publications (1)

Publication Number Publication Date
CA2304312A1 true CA2304312A1 (fr) 1999-03-25

Family

ID=26738426

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304312A Abandoned CA2304312A1 (fr) 1997-09-17 1998-09-17 Acides nucleiques s'hybridant a des cibles multiples, leur preparation, compositions, formulation, trousses et applications

Country Status (8)

Country Link
EP (1) EP1019065A4 (fr)
JP (1) JP2003517428A (fr)
KR (1) KR20010030622A (fr)
AU (1) AU752531B2 (fr)
BR (1) BR9812650A (fr)
CA (1) CA2304312A1 (fr)
IL (1) IL135140A0 (fr)
WO (1) WO1999013886A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230041342A1 (en) * 2020-01-08 2023-02-09 Microvascular Therapeutics, Llc Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518017B1 (en) 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
CA2235420A1 (fr) * 1998-06-17 1999-12-17 Paolo Renzi Oligonucleoside antisens pour traiter ou prevenir les maladies atopiques et la proliferation de cellules neoplastiques
US20040043948A1 (en) * 2001-09-24 2004-03-04 Isis Pharmaceuticals Inc. Antisense modulation of interleukin 8 expression
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US8273866B2 (en) * 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20030060438A1 (en) * 2000-08-18 2003-03-27 Henry James L. Oligonucleotides and other modulators of the NK-1 receptor pathway and therapeutic uses thereof
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (fr) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Inhibition a mediation par interference d'arn de genes de map kinase
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8232383B2 (en) 2002-02-20 2012-07-31 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
WO2004011613A2 (fr) * 2002-07-29 2004-02-05 Epigenesis Pharmaceuticals, Inc. Composition et procedes de traitement et de criblage
US7923547B2 (en) 2002-09-05 2011-04-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003287169A1 (en) * 2002-10-18 2004-05-04 Genta Salus Llc Inhibitory oligonucleotides targeted to matrix metalloproteinase-9
WO2004043353A2 (fr) * 2002-11-06 2004-05-27 Ludwig Institute For Cancer Research Compositions et methodes de traitement de la leucemie aigue myeloide
CA2421086A1 (fr) * 2003-02-28 2004-08-28 Institut Pasteur Promoteur de l'arn polymerase i de poulet et son utilisation
US7399853B2 (en) * 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
US8575327B2 (en) 2003-06-12 2013-11-05 Alnylam Pharmaceuticals, Inc. Conserved HBV and HCV sequences useful for gene silencing
WO2006045202A1 (fr) 2004-10-29 2006-05-04 Topigen Pharmaceuticals Inc. Oligonucleotides antisens pour le traitement d'allergies et de proliferation de cellules neoplastiques
CA2597845A1 (fr) * 2005-02-25 2006-08-31 Isis Pharmaceuticals, Inc. Compositions et leurs utilisations ciblees sur il 4r-alpha
EP2265291B1 (fr) 2008-03-17 2016-10-19 The Board of Regents of The University of Texas System Identification des micro-arn dans l'entretien et la régénération de synapses neuromusculaires
CN102712925B (zh) * 2009-07-24 2017-10-27 库尔纳公司 通过抑制sirtuin(sirt)的天然反义转录物来治疗sirtuin(sirt)相关性疾病
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2015130832A1 (fr) * 2014-02-25 2015-09-03 The Regents Of The University Of California Agents permettant d'améliorer la production de précurseurs de biocarburant dans des micro-algues
KR102545316B1 (ko) 2014-11-10 2023-06-22 알닐람 파마슈티칼스 인코포레이티드 Ｂ형 간염 바이러스(ｈｂｖ) ｉｒｎａ 조성물 및 그의 이용 방법
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
US10350307B2 (en) * 2017-09-18 2019-07-16 General Electric Company In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides
JP7625512B2 (ja) 2018-08-13 2025-02-03 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｂ型肝炎ウイルス（ＨＢＶ）ｄｓＲＮＡ物質組成物およびその使用方法
AU2020271894A1 (en) 2019-04-11 2021-12-02 Enclear Therapies, Inc. Methods of amelioration of cerebrospinal fluid and devices and systems therefor
CN110527630B (zh) * 2019-05-24 2021-04-20 浙江工业大学 一株利用artp诱变技术选育的藤仓赤霉菌突变株及应用
US12329930B2 (en) 2020-09-29 2025-06-17 Enclear Therapies, Inc. Subarachnoid fluid management method and system
AU2022297513A1 (en) * 2021-06-23 2024-01-18 Enclear Therapies, Inc. Method of regulating gene expression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210273D0 (en) * 1992-05-13 1992-07-01 Ici Plc Dna
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US6025339A (en) * 1995-06-07 2000-02-15 East Carolina University Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6040296A (en) * 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230041342A1 (en) * 2020-01-08 2023-02-09 Microvascular Therapeutics, Llc Alkylated nucleosides, and compositions and methods thereof for nucleic acid delivery

Also Published As

Publication number Publication date
KR20010030622A (ko) 2001-04-16
EP1019065A1 (fr) 2000-07-19
IL135140A0 (en) 2001-05-20
EP1019065A4 (fr) 2002-02-20
BR9812650A (pt) 2000-08-22
AU752531B2 (en) 2002-09-19
AU9395198A (en) 1999-04-05
WO1999013886A1 (fr) 1999-03-25
WO1999013886B1 (fr) 1999-04-22
JP2003517428A (ja) 2003-05-27

Similar Documents

Publication Publication Date Title
CA2304312A1 (fr) Acides nucleiques s'hybridant a des cibles multiples, leur preparation, compositions, formulation, trousses et applications
CA2223776C (fr) Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens
US6025339A (en) Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US8101585B2 (en) Compositions and methods for the modulation of JNK proteins
US6040296A (en) Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
KR102662590B1 (ko) 골증식성 장애 및 골증식성 신생물의 치료를 위한 텔로메라제 저해제들의 용도
US20070021360A1 (en) Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase
AU766084B2 (en) Modulation of gene expression by combination therapy
US6825174B2 (en) Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
JP2002539846A (ja) インターロイキン−５シグナルトランスダクションのアンチセンスモジュレーション
JP2010522245A (ja) ヒトアポリポタンパク質ｂと相補的なアンチセンスオリゴヌクレオチドの投与
US20040049022A1 (en) Composition & methods for treatment and screening
US20030096777A1 (en) Modulation of gene expression by combination therapy
EP1011608A2 (fr) Composition et procede pour la prevention et le traitement de l'insuffisance cardio-pulmonaire et renale, ou des lesions consecutives a l'ischemie, la liberation d'endotoxines, l'emphyseme pulmonaire ou a l'administration de certains medicaments
CN101589143A (zh) 用于治疗高胆固醇血症的方法
CA2366055A1 (fr) Procede de validation/d'invalidation de cibles et des voies
JPH11512601A (ja) 修飾プロテインキナーゼａ特異的オリゴヌクレオチドおよびその使用法
CN101087623B (zh) 用于治疗变态反应和肿瘤细胞增殖的反义寡核苷酸
MXPA00002640A (en) Multiple target hybridizing nucleic acids, their preparation, compositions, formulation, kits and applications
US20050014711A1 (en) Composition, formulations & methods for prevention and treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) and inflammation
AU724817B2 (en) Method of treatment for asthma
AU2004200032B2 (en) Modulation of gene expression by combination therapy
AU2006299345A1 (en) Combination therapy using budesonide and antisense oligonucleotide targeted to IL4-receptor alpha
EP1243290A2 (fr) Modulation de l'expression génétique par thérapie combinée
AU7174900A (en) Low adenosine oligonucleotide, composition, kit and methods for obtaining oligonucleotide and for treatment of airway disease(s)

Legal Events

Date Code Title Description
FZDE Discontinued